MedTrace Logo

PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE

NCT04601467 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 243

Last updated 2025-04-27

No results posted yet for this study

Summary

This is a multi-center study conducted at 8 sites in 2 countries (Singapore, New Zealand). Patients with an acute myocardial infarction (AMI) were randomized in a ratio of 1:1 ratio to receive AZD5718 (Atuliflapon) 125 mg or placebo for 12 months to assess the efficacy of AZD5718 to prevent coronary plaque progression as measured on serial computer tomographic coronary angiography.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

AZD5718

Oral dose of AZD5718 (tablet) once daily for 12 months

DRUG

Placebo

Oral dose of matching placebo (tablet) once daily for 12 months

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University of Otago

    collaborator OTHER

  • National University Heart Centre, Singapore

    lead OTHER

Principal Investigators

  • Mark Chan · National University Heart Centre, Singapore

  • Derek Hausenloy · National Heart Centre Singapore

  • A. Mark Richards · National University Heart Centre, Singapore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-12
Primary Completion
2024-05-27
Completion
2024-08-14

Countries

  • New Zealand
  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04601467 on ClinicalTrials.gov